Axsome Therapeutics/$AXSM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Ticker
$AXSM
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
712
ISIN
US05464T1043
Website
AXSM Metrics
BasicAdvanced
$5.1B
-
-$5.77
0.45
-
Price and volume
Market cap
$5.1B
Beta
0.45
52-week high
$139.13
52-week low
$72.21
Average daily volume
646K
Financial strength
Current ratio
2.028
Quick ratio
1.895
Long term debt to equity
392.749
Total debt to equity
397.015
Interest coverage (TTM)
-22.26%
Profitability
EBITDA (TTM)
-230.961
Gross margin (TTM)
91.49%
Net profit margin (TTM)
-64.39%
Operating margin (TTM)
-55.36%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
-26.18%
Return on equity (TTM)
-282.16%
Valuation
Price to revenue (TTM)
11.548
Price to book
95.61
Price to tangible book (TTM)
-1,223.15
Price to free cash flow (TTM)
-41.999
Free cash flow yield (TTM)
-2.38%
Free cash flow per share (TTM)
-246.10%
Growth
Revenue change (TTM)
72.16%
Earnings per share change (TTM)
-9.68%
3-year earnings per share growth (CAGR)
15.74%
10-year earnings per share growth (CAGR)
25.28%
What the Analysts think about AXSM
Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.
Bulls say / Bears say
Axsome Therapeutics' lead product, AUVELITY, has demonstrated strong commercial performance in treating major depressive disorder, with third-quarter 2024 revenues reaching $104.8 million, surpassing analyst projections. (Investing.com)
The FDA approved Axsome's migraine treatment, Symbravo, in January 2025, expanding the company's product portfolio and potential revenue streams. (Reuters)
Analysts have raised their price targets for Axsome, with Needham & Company LLC increasing it to $153.00, reflecting confidence in the company's growth prospects. (MarketBeat)
Axsome's reliance on the success of key products, particularly AXS-05, poses a risk; any setbacks in clinical trials or regulatory approvals could significantly impact the company's growth prospects. (Investing.com)
The company's high debt-to-equity ratio of 132% raises concerns about financial stability and the ability to manage obligations effectively. (Yahoo Finance)
Increased competition in the CNS therapeutics market, including potential new entrants and existing competitors enhancing their offerings, may challenge Axsome's ability to maintain market share. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
AXSM Financial Performance
Revenues and expenses
AXSM Earnings Performance
Company profitability
AXSM News
AllArticlesVideos
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
GlobeNewsWire·1 week ago
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
GlobeNewsWire·3 weeks ago
Axsome Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Axsome Therapeutics stock?
Axsome Therapeutics (AXSM) has a market cap of $5.1B as of June 30, 2025.
What is the P/E ratio for Axsome Therapeutics stock?
The price to earnings (P/E) ratio for Axsome Therapeutics (AXSM) stock is 0 as of June 30, 2025.
Does Axsome Therapeutics stock pay dividends?
No, Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Axsome Therapeutics dividend payment date?
Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Axsome Therapeutics?
Axsome Therapeutics (AXSM) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.